Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01679054Completed

Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong

Role: lead

NCT01801085Terminated

Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens

Role: lead

NCT02063412Withdrawn

Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens

Role: lead

All 3 trials loaded